MDMA-assisted therapy

Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically authorized psychiatrists to treat certain mental health conditions, such as ...

Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, several publicly listed companies are developing related products such as next-generation psychedelics- or a new delivery...

The legendary non-profit’s private arm, MAPS Public Benefit Corporation (MAPS PBC), announced that Frontiers in Psychiatry has published its first functional neuroimaging study evaluating how MDMA-assisted therapy works in people with PTSD. The MAPS study aimed at assessing how MDMA...

Guess Which East Coast State Is Now Discussing Legalizing Psychedelics? Decriminalizing psychedelics is one thing, but fully legalizing them is another. That's currently a measure before New York's Senate Health Committee. By prefiling the bill, Democratic sponsors Reps. Linda Rosenthal, Jo...

MAPS Public Benefit Corporation (MAPS PBC), the non-profit’s private biopharma leg developing psychedelic medicines, announced positive results from MAPP2, the company’s second Phase 3 study assessing MDMA-assisted therapy for PTSD.  "The Phase 3 confirmatory results support...

Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy Elon Musk continues touting the benefits of psychedelics, from his live interview at CodeCon2021 to his most recent tweets endorsing those working towards developing these substances for better therapeutic effects and...

MAPS Public Benefit Corporation (PBC) announced the final participant’s last Evaluation and Exit Planning therapeutic session was completed in MAPP2, a multi-site Phase 3 study of MDMA-assisted therapy for the treatment of Post-Traumatic Stress Disorder (PTSD.) A wholly-owned subsidiary...

Atai Life Sciences' (NASDAQ: ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant enrollment in its Phase 1 trial of proprietary MDMA-based drug EMP-01, designed to ...

Biotech firm leading the Alcohol Use Disorder (AUD) treatment Awakn Life Sciences Corp. (OTCQB: AWKNF) has announced its financial outcomes and business highlights for the three months ended July 31, 2022. During the period, numbers reflected: Total revenue of $255.719 through its London, Bristol...

Nirvana Life Sciences Inc. (CSE: NIRV) announced that it has engineered a method that reduces the manufacturing time of MDMA by two thirds. The 3-step synthesis starts from the MDMA precursor safrole and takes only 24 hours to complete depending on which reduction method of...

Health Canada has just completed a review of all active MDMA-assisted psychotherapy trials, in response to alleged patient safety issues and research flaws. The issues had resulted in one of the two existing studies being suspended while the other allowed to proceed with some "corrective...

Rep. Michael Davis (R) on Wednesday filed a bill to give residents with serious illnesses legal access to a range of psychedelic drugs like psilocybin, ibogaine and LSD through an expanded version of the state’s existing right-to-try law, reported Marijuana Moment. “There is emerging...

The Australian state of Victoria faces a seminal lawsuit that seeks to make MDMA available for severe mental illness. Attempting to secure permission to treat a gravely ill patient using MDMA (universally known as the street drug ecstasy), psychiatrist Dr. Eli Kotler initiated legal...